Dupont Capital Management Corp Nektar Therapeutics Transaction History

Dupont Capital Management Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Oct 29, 2020	SELL	$16.59 - $24.79 $78,304 - $117,008	-4,720 Closed	0 $0
Q2 2020 Jul 24, 2020	BUY	$16.86 - $23.44 $4,063 - $5,649	241 Added 5.38%	4,720 $109,000
Q1 2020 Apr 29, 2020	BUY	$14.47 - $27.96 $64,811 - $125,232	4,479 New	4,479 $80,000
Q4 2018 Feb 01, 2019	SELL	$30.43 - $56.65 $52,248 - $97,268	-1,717 Closed	0 $0
Q2 2018 Jul 30, 2018	SELL	$46.25 - $104.45 $631,728 - $1.43 Million	-13,659 Reduced 88.83%	1,717 $84,000

Q1 2018 May 02, 2018	BUY	$57.4 - $108.44 $882,582 - $1.67 Million	15,376 New	15,376 $1.63 Million

128

111M

150K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $231M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Dupont Capital Management Corp, based on Form 13F filings with the SEC.

Stay updated on Dupont Capital Management Corp with notifications on news.